AbbVie (ABBV) — 8-K — Material Event

AbbVie (NYSE: ABBV) announced it will acquire Apogee Therapeutics (NASDAQ: APGE) for $135.11 per share, valuing the deal at approximately $10.9 billion. The acquisition aims to strengthen AbbVie's immunology portfolio, particularly in respiratory diseases. The transaction is expected to close in Q3 2026, pending shareholder and regulatory approvals.

• •AbbVie to acquire Apogee for $135.11 per share.
• •Total equity value of the deal is approximately $10.9 billion.
• •Acquisition focuses on immunology treatments for asthma and atopic dermatitis.
• •Transaction expected to close in Q3 2026, pending approvals.

The acquisition will provide AbbVie with new clinical-stage assets, enhancing its ability to address significant patient needs in immunology. This could lead to increased revenue from new treatments.